vs

Side-by-side financial comparison of EXACT SCIENCES CORP (EXAS) and Match Group (MTCH). Click either name above to swap in a different company.

EXACT SCIENCES CORP is the larger business by last-quarter revenue ($878.4M vs $878.0M, roughly 1.0× Match Group). Match Group runs the higher net margin — 23.9% vs -9.8%, a 33.7% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs 2.1%). Match Group produced more free cash flow last quarter ($308.1M vs $120.4M). Over the past eight quarters, EXACT SCIENCES CORP's revenue compounded faster (17.4% CAGR vs 1.1%).

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.

Match Group, Inc. is an American internet and technology company headquartered in Dallas, Texas. It owns and operates the largest global portfolio of popular online dating services including Tinder, Match.com, Meetic, OkCupid, Hinge, Plenty of Fish, Azar, and other dating global brands. The company was owned by IAC until July 2020 when Match Group was spun off as a separate, public company. As of 2019, the company had 9.3 million subscribers, of which 4.6 million were in North America. Japan ...

EXAS vs MTCH — Head-to-Head

Bigger by revenue
EXAS
EXAS
1.0× larger
EXAS
$878.4M
$878.0M
MTCH
Growing faster (revenue YoY)
EXAS
EXAS
+21.0% gap
EXAS
23.1%
2.1%
MTCH
Higher net margin
MTCH
MTCH
33.7% more per $
MTCH
23.9%
-9.8%
EXAS
More free cash flow
MTCH
MTCH
$187.7M more FCF
MTCH
$308.1M
$120.4M
EXAS
Faster 2-yr revenue CAGR
EXAS
EXAS
Annualised
EXAS
17.4%
1.1%
MTCH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EXAS
EXAS
MTCH
MTCH
Revenue
$878.4M
$878.0M
Net Profit
$-86.0M
$209.7M
Gross Margin
70.1%
74.7%
Operating Margin
-9.4%
32.4%
Net Margin
-9.8%
23.9%
Revenue YoY
23.1%
2.1%
Net Profit YoY
90.1%
32.5%
EPS (diluted)
$-0.45
$0.83

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXAS
EXAS
MTCH
MTCH
Q4 25
$878.4M
$878.0M
Q3 25
$850.7M
$914.3M
Q2 25
$811.1M
$863.7M
Q1 25
$706.8M
$831.2M
Q4 24
$713.4M
$860.2M
Q3 24
$708.7M
$895.5M
Q2 24
$699.3M
$864.1M
Q1 24
$637.5M
$859.6M
Net Profit
EXAS
EXAS
MTCH
MTCH
Q4 25
$-86.0M
$209.7M
Q3 25
$-19.6M
$160.8M
Q2 25
$-1.2M
$125.5M
Q1 25
$-101.2M
$117.6M
Q4 24
$-864.6M
$158.3M
Q3 24
$-38.2M
$136.5M
Q2 24
$-15.8M
$133.3M
Q1 24
$-110.2M
$123.2M
Gross Margin
EXAS
EXAS
MTCH
MTCH
Q4 25
70.1%
74.7%
Q3 25
68.6%
73.0%
Q2 25
69.3%
72.0%
Q1 25
70.8%
71.5%
Q4 24
69.0%
72.5%
Q3 24
69.4%
71.7%
Q2 24
69.8%
71.6%
Q1 24
70.0%
70.1%
Operating Margin
EXAS
EXAS
MTCH
MTCH
Q4 25
-9.4%
32.4%
Q3 25
-3.0%
24.2%
Q2 25
-0.3%
22.5%
Q1 25
-13.6%
20.8%
Q4 24
-122.8%
26.0%
Q3 24
-5.6%
23.5%
Q2 24
-3.8%
23.7%
Q1 24
-16.7%
21.5%
Net Margin
EXAS
EXAS
MTCH
MTCH
Q4 25
-9.8%
23.9%
Q3 25
-2.3%
17.6%
Q2 25
-0.1%
14.5%
Q1 25
-14.3%
14.1%
Q4 24
-121.2%
18.4%
Q3 24
-5.4%
15.2%
Q2 24
-2.3%
15.4%
Q1 24
-17.3%
14.3%
EPS (diluted)
EXAS
EXAS
MTCH
MTCH
Q4 25
$-0.45
$0.83
Q3 25
$-0.10
$0.62
Q2 25
$-0.01
$0.49
Q1 25
$-0.54
$0.44
Q4 24
$-4.69
$0.59
Q3 24
$-0.21
$0.51
Q2 24
$-0.09
$0.48
Q1 24
$-0.60
$0.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXAS
EXAS
MTCH
MTCH
Cash + ST InvestmentsLiquidity on hand
$964.7M
$1.0B
Total DebtLower is stronger
$3.5B
Stockholders' EquityBook value
$2.4B
$-253.5M
Total Assets
$5.9B
$4.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXAS
EXAS
MTCH
MTCH
Q4 25
$964.7M
$1.0B
Q3 25
$1.0B
$1.1B
Q2 25
$858.4M
$340.4M
Q1 25
$786.2M
$414.2M
Q4 24
$1.0B
$970.7M
Q3 24
$1.0B
$860.9M
Q2 24
$946.8M
$843.6M
Q1 24
$652.1M
$920.9M
Total Debt
EXAS
EXAS
MTCH
MTCH
Q4 25
$3.5B
Q3 25
Q2 25
Q1 25
$3.4B
Q4 24
$3.8B
Q3 24
$3.8B
Q2 24
$3.8B
Q1 24
$3.8B
Stockholders' Equity
EXAS
EXAS
MTCH
MTCH
Q4 25
$2.4B
$-253.5M
Q3 25
$2.5B
$-223.9M
Q2 25
$2.5B
$-230.9M
Q1 25
$2.4B
$-182.7M
Q4 24
$2.4B
$-63.7M
Q3 24
$3.2B
$-88.5M
Q2 24
$3.2B
$-130.2M
Q1 24
$3.1B
$-107.8M
Total Assets
EXAS
EXAS
MTCH
MTCH
Q4 25
$5.9B
$4.5B
Q3 25
$5.9B
$4.5B
Q2 25
$5.8B
$3.9B
Q1 25
$5.7B
$3.9B
Q4 24
$5.9B
$4.5B
Q3 24
$6.7B
$4.4B
Q2 24
$6.7B
$4.4B
Q1 24
$6.4B
$4.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXAS
EXAS
MTCH
MTCH
Operating Cash FlowLast quarter
$151.7M
$322.8M
Free Cash FlowOCF − Capex
$120.4M
$308.1M
FCF MarginFCF / Revenue
13.7%
35.1%
Capex IntensityCapex / Revenue
3.6%
1.7%
Cash ConversionOCF / Net Profit
1.54×
TTM Free Cash FlowTrailing 4 quarters
$356.8M
$1.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXAS
EXAS
MTCH
MTCH
Q4 25
$151.7M
$322.8M
Q3 25
$219.9M
$320.6M
Q2 25
$89.0M
$243.8M
Q1 25
$30.8M
$193.1M
Q4 24
$47.1M
$254.7M
Q3 24
$138.7M
$264.9M
Q2 24
$107.1M
$129.0M
Q1 24
$-82.3M
$284.1M
Free Cash Flow
EXAS
EXAS
MTCH
MTCH
Q4 25
$120.4M
$308.1M
Q3 25
$190.0M
$306.8M
Q2 25
$46.7M
$231.0M
Q1 25
$-365.0K
$177.7M
Q4 24
$10.7M
$247.1M
Q3 24
$112.6M
$251.8M
Q2 24
$71.2M
$116.3M
Q1 24
$-120.0M
$266.9M
FCF Margin
EXAS
EXAS
MTCH
MTCH
Q4 25
13.7%
35.1%
Q3 25
22.3%
33.6%
Q2 25
5.8%
26.7%
Q1 25
-0.1%
21.4%
Q4 24
1.5%
28.7%
Q3 24
15.9%
28.1%
Q2 24
10.2%
13.5%
Q1 24
-18.8%
31.0%
Capex Intensity
EXAS
EXAS
MTCH
MTCH
Q4 25
3.6%
1.7%
Q3 25
3.5%
1.5%
Q2 25
5.2%
1.5%
Q1 25
4.4%
1.9%
Q4 24
5.1%
0.9%
Q3 24
3.7%
1.5%
Q2 24
5.1%
1.5%
Q1 24
5.9%
2.0%
Cash Conversion
EXAS
EXAS
MTCH
MTCH
Q4 25
1.54×
Q3 25
1.99×
Q2 25
1.94×
Q1 25
1.64×
Q4 24
1.61×
Q3 24
1.94×
Q2 24
0.97×
Q1 24
2.31×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXAS
EXAS

Screening$695.1M79%
Precision Oncology$183.2M21%

MTCH
MTCH

Tinder Segment$479.3M55%
Hinge Segment$186.5M21%
Evergreen And Emerging Segment$148.1M17%
MG Asia Segment$65.8M7%

Related Comparisons